아시아태평양의 간질 치료제 시장 예측(-2030년) : 지역별 분석 - 치료별, 유통 채널별

The Asia Pacific epilepsy drugs market was valued at US$ 2,198.72 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to grow at a CAGR of 4.6% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Asia Pacific Epilepsy Drugs Market

Many patents expiries are anticipated in the epilepsy drugs market in the upcoming years. It is likely to increase the penetration of generic products to cut down healthcare expenses. This will generate additional opportunities for other market players. Below mentioned are some drugs that are nearing patent expiration in the next couple of years.

Company Patent Patent Expiration Date Ingredient Treatment

Sumitomo Pharma Co US9206135 April 21, 2026 ESLICARBAZEPINE ACETATE Partial-onset Seizures Epilepsy

GlaxoSmithKline US7919115 January 4, 2029 LAMOTRIGINE Epilepsy

Ucb Inc USRE38551 March 17, 2022 Lacosamide Epilepsy and Partial-onset Seizures

SK Biopharmaceuticals US7598279 October 30, 2027 CENOBAMATE Partial Epilepsies

SUPERNUS PHARMS US8877248 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9555004 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US10314790 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8663683 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9622983 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298580 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8992989 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8889191 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US9549940 November, 2027 Sustained-release formulations of Topiramate Epilepsy

SUPERNUS PHARMS US8298576 April, 2028 Sustained-release formulations of Topiramate Epilepsy

Asia Pacific Epilepsy Drugs Market Overview

The Asia Pacific epilepsy drugs market is analysed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world and the one with the most patients with neurological disorders. According to the Centers of Disease Control and Prevention, in China, the prevalence rate of active epilepsy is 0.48% to 8.5%; there are approximately 9 million people with epilepsy in Mainland China, two-thirds of whom are children. ~30% of patients with epilepsy are not capable of controlling their seizures with the AEDs that are currently available in the market; thus, this disease has significant unmet medical needs.

Moreover, the drug approvals in the country are propelling the market growth. For instance, in August 2021, Eisai Co., Ltd. obtained two additional approvals of the antiepileptic drug (AED) Fycompa, as "a monotherapy for partial-onset seizures" and "an adjunctive treatment / a monotherapy for a pediatric indication for partial onset seizures in patients with epilepsy four years of age and older" in China from the National Medical Products Administration.

Asia Pacific Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Drugs Market Segmentation

The Asia Pacific epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Asia Pacific epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Asia Pacific epilepsy drugs market is segmented China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific epilepsy drugs market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Epilepsy Drugs Market Landscape

• 4.1 Overview

5. Asia Pacific Epilepsy Drugs Market - Key Industry Dynamics

• 5.1 Market Drivers
  • 5.1.1 Growing Prevalence of Epilepsy
  • 5.1.2 Increasing Number of Elderly People
• 5.2 Market Restraints
  • 5.2.1 Recall of Therapeutic Products
• 5.3 Market Opportunities
  • 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
• 5.4 Future Trends
  • 5.4.1 Increasing Product Approvals
• 5.5 Impact Analysis

6. Epilepsy Drugs Market - Asia Pacific Market Analysis

• 6.1 Overview
• 6.2 Asia Pacific Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

• 7.1 Overview
• 7.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
• 7.3 First Generation Antiepileptics
  • 7.3.1 Overview
  • 7.3.2 First Generation Antiepileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Second Generation Anti-epileptics
  • 7.4.1 Overview
  • 7.4.2 Second Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Third Generation Anti-epileptics
  • 7.5.1 Overview
  • 7.5.2 Third Generation Anti-epileptics: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

• 8.1 Overview
• 8.2 Asia Pacific Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 8.3 Hospital Pharmacy
  • 8.3.1 Overview
  • 8.3.2 Hospital Pharmacy: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Retail Pharmacy Stores
  • 8.4.1 Overview
  • 8.4.2 Retail Pharmacy Stores: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

• 9.1 Asia Pacific Epilepsy Drugs Market, by Key Country- Revenue (2022) (US$ Million)
  • 9.1.1 Asia Pacific Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
    • 9.1.1.1 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.1 Overview
      • 9.1.1.1.2 China: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.1.3 China: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.1.4 China: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.1 Overview
      • 9.1.1.2.2 Japan: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.2.3 Japan: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.2.4 Japan: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.3 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.1 Overview
      • 9.1.1.3.2 India: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.3.3 India: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.3.4 India: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.4 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.1 Overview
      • 9.1.1.4.2 Australia: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.4.3 Australia: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.4.4 Australia: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.5 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.1 Overview
      • 9.1.1.5.2 South Korea: Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.5.3 South Korea: Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.5.4 South Korea: Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
    • 9.1.1.6 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.1 Overview
      • 9.1.1.6.2 Rest of Asia Pacific Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.1.6.3 Rest of Asia Pacific Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
      • 9.1.1.6.4 Rest of Asia Pacific Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

• 10.1 Overview
• 10.2 Growth Strategies in the Epilepsy Drugs Market
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview
• 10.4 Organic Growth Strategies
  • 10.4.1 Overview

11. Company Profiles

• 11.1 Novartis AG
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 Pfizer Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 GSK Plc
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Abbott Laboratories
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Sanofi SA
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Teva Pharmaceutical Industries Ltd
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Alkem Laboratories Ltd
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments

12. Appendix

• 12.1 About Us
• 12.2 Glossary of Terms